PRESS RELEASE

from ABIVAX (EPA:ABVX)

Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023

EQS-News: ABIVAX / Key word(s): Miscellaneous
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023

15.06.2023 / 22:41 CET/CEST
The issuer is solely responsible for the content of this announcement.


Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023

  • The award recognizes a significant capital market transaction in the biotech sector
  • Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023

PARIS, France, June 15, 2023 – Abivax (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today that it received the “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023. This award recognizes a significant capital market transaction taking into account the amount of money raised, stock price performance and the quality of the share register.

Abivax received the award for its EUR 130M oversubscribed capital increase at market price in February 2023. The financing round was led by TCGX, with participation from existing investors such as Sofinnova Partners, Invus, Deep Track Capital, Venrock Healthcare Capital Partners, as well as from new investors such as Great Point Partners LLC, Deerfield Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others.

Didier Blondel, CFO of Abivax, said: “We are proud and feel honored to receive the “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023. We were very pleased that Abivax could attract top-tier U.S. and European biotech investors for this transaction which, we believe, is a valuable recognition of the remarkable clinical achievements with obefazimod during the past months and years. The Company’s strategic priority at present is the completion of our global Phase 3 clinical program of obefazimod for the treatment of ulcerative colitis. The entire Abivax team stays committed to bringing obefazimod to the market for the benefit of the many UC patients in need of safe and long-term efficient treatment options.”

*****

About the European Mediscience Awards 2023

The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognize success. Each year sees the attendance of over 500 public and private European life sciences companies and their corporate advisers, analysts, fund managers, commentators and peers.


About Abivax (www.abivax.com)

Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.


Contacts

Abivax                 
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
 
Investors
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310
 
Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22
 
Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24
Public Relations France
Primatice
Thomas Roborel de Climens
thomasdeclimens@primatice.com
+33 6 78 12 97 95
Public Relations USA     
Rooney Partners LLC
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646 770 8858


15.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1656273  15.06.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1656273&application_name=news&site_id=symex
See all ABIVAX news